İsrail - İbranice - Ministry of Health

csl behring ltd., israel - factor xiii - powder for solution for injection - factor xiii 200 - 320 iu - coagulation factor xiii - coagulation factor xiii - congenital or acquired factor xiii deficiency, or to promote healing of wounds and bone fractures. congenital deficiency of factor xiii and resultant haemorrhagic syndroms

İsrail - İbranice - Ministry of Health

csl behring ltd., israel - factor xiii - powder for solution for injection - factor xiii 1250 iu - coagulation factor xiii - coagulation factor xiii - congenital or acquired factor xiii deficiency or to promote healing of wounds and bone fractures. congenital deficiency of factor xiii and resultant haemorrhagic syndroms

İsrail - İbranice - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 250 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

İsrail - İbranice - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 500 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup).benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

İsrail - İbranice - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 1000 iu/vial - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

İsrail - İbranice - Ministry of Health

pfizer pharmaceuticals israel ltd - coagulation factor ix recombinant-rfix - אבקה מיובשת בהקפאה להזרקה - coagulation factor ix recombinant-rfix 2000 iu - coagulation factor ix - coagulation factor ix - benefix is indicated for the control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings, in previously treated patients (ptp) and previously untreated patients (pup). benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii,vii, and x)' nor for the treatment of hemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin-induced anticoagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.

İsrail - İbranice - Ministry of Health

bayer israel ltd - antihemophilic factor (recombinant) sucrose - אבקה להכנת תמיסה לזריקה - antihemophilic factor (recombinant) sucrose 500 iu/vial - blood coagulation factors - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor viii.routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with severe hemophilia a with no pre-existing joint damage. kogenate fs is not indicated for the treatment of von willebrand’s disease.

İsrail - İbranice - Ministry of Health

bayer israel ltd - antihemophilic factor (recombinant) sucrose - אבקה להכנת תמיסה לזריקה - antihemophilic factor (recombinant) sucrose 1000 iu/vial - blood coagulation factors - for the treatment of classical hemophilia (hemophilia a) in which there is a demonstrated deficiency of activity of the plasma clotting factor viii.routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children under with severe hemophilia a with no pre-existing joint damage.kogenate fs is not indicated for the treatment of von willebrand’s disease.

İsrail - İbranice - Ministry of Health

takeda israel ltd - octocog alfa (antihemophilic factor recombinant) - אבקה להכנת תמיסה לזריקה - octocog alfa (antihemophilic factor recombinant) 500 iu/vial - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).

İsrail - İbranice - Ministry of Health

takeda israel ltd - octocog alfa (antihemophilic factor recombinant) - אבקה להכנת תמיסה לזריקה - octocog alfa (antihemophilic factor recombinant) 1000 iu/vial - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).